The following is a summary of “Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) with UGN-101, A Mitomycin Reverse Thermal Gel,” published in the November 2024 issue of Urology by Pierorazio et al. 

Researchers conducted a retrospective study to evaluate long-term outcomes of primary chemoablation with UGN-101 in low-grade upper tract urothelial carcinoma (LG UTUC). 

They involved patients from the OLYMPUS trial (TC-UT-03, NCT02793128) who achieved a complete response after 6 weekly doses of UGN-101 for up to 12 months. Patients with a complete response at study completion were eligible for long-term follow-up for up to 5 years or until disease recurrence, progression, or death. 

The results showed that 42 of 71 patients achieved complete response 4-6 weeks after ≥1 UGN-101 instillation. Among 41 patients followed, the median follow-up was 28.1 months (95% CI 13.1, 57.5), and median duration of response was 47.8 months (95% CI 13.0, not estimable). Of 20 patients with long-term follow-up (median 53.3 months [95% CI 27.9, 65.3]), 75% had no recurrence at last follow-up, with median duration of response not estimable (95% CI 43.5, not estimable). 

They concluded that primary intracavitary chemoablation with UGN-101 for LG UTUC demonstrated favorable long-term durability.  

Source: auajournals.org/doi/10.1097/JU.0000000000004331